PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PharmAla Biotech Holdings Inc. reports a tenfold revenue increase in Q3 and solidifies its market presence by securing new opportunities in international markets. The biotech firm has strengthened its position through a permanent joint venture with Cortexa and the issuance of a US patent for its novel molecule, APA-01, which shows promise for treating a range of indications. Additionally, PharmAla acknowledges the support from IPON in securing global patents and announces a new contract and share grant for its CEO.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.